Absolute Spectral Power during relaxation (eyes open) 0h before acute intake at day A

Delta

Theta

Alpha1

Alpha2

Beta1

Beta2

Subjects

n = 20

n = 20

n = 20

n = 20

n = 20

n = 20

n = 20

n = 20

n = 20

n = 20

n = 20

n = 20

Electrode

Placebo

Verum

Placebo

Verum

Placebo

Verum

Placebo

Verum

Placebo

Verum

Placebo

Verum

Cz

1.46

1.49

1.25

1.13

1.06

0.97

0.74

0.70

0.71

0.54

0.91

0.96

Fz

2.37

2.31

1.57

1.65

1.04

1.32

0.67

0.79

0.75

0.67

1.02

0.93

F3

1.74

2.23

1.09

1.49

0.82

1.12

0.62

0.83

0.81

0.88

2.02

1.49

C3

0.98

1.04

0.84

0.86

0.89

0.81

1.16

0.73

1.10

0.95

1.27

1.54

P3

0.73

0.72

0.52

0.58

0.47

0.57

0.46

0.65

0.45

0.62

0.50

0.69

Pz

1.15

0.92

0.79

0.77

0.65

0.95

0.65

1.25

0.84

0.79

0.71

0.64

P4

0.77

0.86

0.52

0.59

0.50

0.91

0.54

0.81

0.73

0.71

0.80

0.71

C4

0.98

1.19

0.74

0.86

0.56

0.94

0.58

0.96

0.89

0.91

1.13

1.24

F4

1.83

1.91

1.34

1.41

1.23

1.06

0.86

0.80

0.88

0.89

1.43

1.53

F7

5.58

6.41

3.28

3.03

1.82

2.01

1.32

1.77

1.69

1.59

2.33

2.38

T3

2.47

2.82

1.89

2.10

1.28

1.63

1.42

1.36

1.85

1.73

1.93

2.41

T5

2.17

1.77

1.58

1.61

1.30

1.36

1.20

1.43

1.64

1.52

1.37

1.53

O1

1.93

2.16

1.34

1.37

1.42

1.10

1.39

1.42

1.36

1.39

1.81

2.05

O2

1.99

2.31

1.39

1.45

0.91

1.75

0.91

2.12

1.28

1.64

1.82

1.76

T6

2.11

2.17

1.43

1.69

1.60

2.11

2.42

3.27

2.22

1.97

1.52

1.87

T4

3.05

2.58

2.00

1.70

1.23

1.37

1.45

1.49

2.01

2.35

2.91

3.92

F8

5.62

5.06

3.08

2.74

1.72

1.92

1.38

2.01

1.78

1.61

3.23

2.82

Med

1.81

2.00

1.24

1.43

1.18

1.12

0.81

1.10

1.15

1.18

1.35

1.48